15.35

1.39% 0.21

After Hours: 14.99 -0.36 -2.35%

Edgewise Therapeutics Inc (EWTX)

Overview News Price History Option Chain Financials Discussions Forecast

Edgewise Therapeutics Inc stock is traded at $15.35, with a volume of 1.16M. It is up +1.39% in the last 24 hours and up +3.16% over the past month. Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Previous Close:

$15.14

Open:

$15.28

24h Volume:

1.16M

Relative Volume:

1.47

Market Cap:

$1.62B

Revenue:

Net Income/Loss:

$-150.70M

P/E Ratio:

-9.9032

EPS:

-1.55

Net Cash Flow:

$-125.67M

1W Performance:

-0.58%

1M Performance:

+3.16%

6M Performance:

+33.59%

1Y Performance:

-46.12%

1-Day Range:

$15.21

$16.03

1-Week Range:

$14.85

$16.03

52-Week Range:

$10.60

$38.12

Edgewise Therapeutics Inc Stock (EWTX) Company Profile

Name

Edgewise Therapeutics Inc

Sector

Healthcare (1141)

Industry

Biotechnology (639)

Phone

720-262-7002

Address

1715 38TH ST, BOULDER

Employee

126

Twitter

Next Earnings Date

2025-03-03

Latest SEC Filings

EWTX's Discussions on Twitter

Compare EWTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EWTX Edgewise Therapeutics Inc	15.35	1.59B	0	-150.70M	-125.67M	-1.55
VRTX Vertex Pharmaceuticals Inc	421.15	105.19B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	450.68	60.24B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	563.86	61.82B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	798.94	49.09B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	351.09	37.52B	4.56B	-176.77M	225.30M	-1.7177

Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-25-25	Initiated	Goldman	Neutral
Jul-30-25	Initiated	Raymond James	Strong Buy
Jun-30-25	Initiated	H.C. Wainwright	Buy
Apr-30-25	Initiated	Guggenheim	Buy
Apr-02-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Jan-22-25	Initiated	Stifel	Hold
Nov-22-24	Initiated	Evercore ISI	Outperform
Mar-07-24	Initiated	Piper Sandler	Overweight
May-01-23	Initiated	Truist	Buy
Aug-25-22	Downgrade	Goldman	Neutral → Sell
Apr-13-22	Initiated	RBC Capital Mkts	Outperform
Jan-28-22	Initiated	Goldman	Neutral

View All

Edgewise Therapeutics Inc Stock (EWTX) Latest News

12:14 PM

Edgewise Therapeutics (EWTX): Evaluating Valuation as New Long-Term Clinical Data Sparks Investor Interest - Yahoo Finance

12:14 PM

Oct 07, 2025

How Investors Are Reacting To Edgewise Therapeutics (EWTX) Unveiling Long-Term Data for Sevasemten at WMS 2025 - Sahm

Oct 07, 2025

Oct 06, 2025

Edgewise Therapeutics presents muscular dystrophy research at Vienna conference - Traders Union

Oct 06, 2025

Oct 05, 2025

Tools to monitor Edgewise Therapeutics Inc. recovery probabilityWeekly Trend Report & Long-Term Growth Stock Strategies - newser.com

Oct 05, 2025

Oct 03, 2025

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - Eastern Progress

Oct 03, 2025

Edgewise Therapeutics (EWTX): Reviewing Valuation After Recent Momentum Shifts - Sahm

Oct 03, 2025